Here are the latest quarterly results of Piramal Enterprises. For more details, see the Piramal Enterprises financial fact sheet and Piramal Enterprises share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Dec-18* |
3
Mar-19* |
3
Jun-19* |
3
Sep-19* |
3
Dec-19* |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 34,891 | 36,797 | 35,063 | 36,036 | 38,057 | 33,410 | 29,373 | 33,018 | |
Other income | Rs m | 1,028 | 852 | 669 | 627 | 1,413 | 2,396 | 655 | 376 | |
Turnover | Rs m | 35,919 | 37,649 | 35,732 | 36,662 | 39,470 | 35,806 | 30,028 | 33,394 | |
Expenses | Rs m | 14,618 | 17,380 | 14,004 | 13,497 | 15,099 | 34,386 | 11,419 | 13,019 | |
Gross profit | Rs m | 20,273 | 19,283 | 20,945 | 22,398 | 22,958 | -976 | 17,955 | 20,395 | |
Depreciation | Rs m | 1,326 | 1,354 | 1,582 | 1,664 | 1,664 | 1,429 | 1,346 | 1,394 | |
Interest | Rs m | 11,688 | 13,157 | 14,085 | 14,182 | 14,417 | 12,953 | 11,046 | 11,558 | |
Profit before tax | Rs m | 8,287 | 5,624 | 5,947 | 7,179 | 8,289 | -12,962 | 6,217 | 7,819 | |
Tax | Rs m | 2,930 | 2,243 | 2,176 | 1,581 | 2,306 | 12,595 | 1,611 | 2,039 | |
Profit after tax | Rs m | 5,356 | 3,381 | 3,771 | 5,598 | 5,983 | -25,557 | 4,606 | 5,781 | |
Gross profit margin | % | 58.1 | 52.4 | 59.7 | 62.2 | 60.3 | -2.9 | 61.1 | 61.8 | |
Effective tax rate | % | 35.4 | 39.9 | 36.6 | 22.0 | 27.8 | -97.2 | 25.9 | 26.1 | |
Net profit margin | % | 15.4 | 9.2 | 10.8 | 15.5 | 15.7 | -76.5 | 15.7 | 17.5 | |
Diluted EPS | Rs | 23.7 | 15.0 | 16.7 | 24.8 | 26.5 | -113.3 | 20.4 | 25.6 | |
Diluted EPS (TTM) | Rs | 214.2 | 54.3 | 76.8 | 80.3 | 83.1 | -45.2 | -41.5 | -40.7 | |
![]() |
Read: Piramal Enterprises 1QFY21 Result Performance Review
More Pharmaceuticals Company Quarterly Results: TORRENT PHARMA SHASUN PHARMA J.B.CHEMICALS WOCKHARDT PROCTER & GAMBLE HEALTH
Compare PIRAMAL ENTERPRISES With: TORRENT PHARMA SHASUN PHARMA J.B.CHEMICALS WOCKHARDT PROCTER & GAMBLE HEALTH
Compare PIRAMAL ENTERPRISES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.
For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More